[Establishment and Characterization of a Novel Chinese Human Lung Adenocarcinoma Cell Line CPA-Yang2 in Immunodeficient Mice.]

[Clinical Assessment of Chemosensitivity Test in Xeno-free Culture of Autologous Malignant Effusion Cells from Patients with Advanced Lung Adenocarcinoma]

背景与目的

晚期肺癌的化疗效果存在极大的个体差异，如何选择最佳化疗方案，实现肺癌化疗的个体化、效果最大化是值得探索的课题。本研究旨在检验自体积液中进行癌细胞培养及药敏试验对于合并胸腔或心包积液的肺腺癌患者优化化疗方案的临床应用价值。

方法

收集50例并发恶性胸腔和/或心包积液的肺腺癌初治患者，经闭式引流控制积液。其中25例（药敏组）于无菌条件下留取积液300 mL-500 mL，肿瘤细胞通过自体积液（xeno-free）平均11天的细胞培养而获得，继而针对8种临床常用化疗药物行药敏试验，通过CCK-8进行敏感性检测，根据试验结果选择最优化疗方案进行全身化疗；另25例（对照组）进行经验性化疗。

结果

4个周期化疗后，药敏组部分缓解（partial response, PR）17例（68.0%）、稳定（stable disease, SD）5例（20.0%），客观缓解率（objective response rate, ORR）68.0%，疾病控制率（disease control rate, DCR）88.0%；对照组PR 9例（36.0%）、SD 7例（28.0%），ORR为36.0%，DCR为64.0%。比较两组ORR和DCR，差异均有统计学意义（P < 0.05）。至随访截止，药敏组死亡21例，对照组死亡22例。药敏组无进展生存期（progression-free survival, PFS）平均10.0个月，总生存期（overall survival, OS）平均30.2个月；对照组PFS平均5.8个月，OS平均21.2个月。比较两组PFS和OS，差异均有统计学意义（P < 0.05）。两组毒副反应轻微、可控。

结论

自体积液癌细胞培养及药敏试验有利于晚期肺腺癌患者化疗方案的合理选择。

[Establishment of a novel chinese human lung adenocarcinoma cell line CPA-Yang3 and its real bone metastasis clone CPA-Yang3BM in immunodeficient mice]

BACKGROUND AND OBJECTIVE

The recurrence and metastasis of lung cancer is a tough problem worldwide. The aim of this study is to establish a novel Chinese lung adenocarcinoma cell line and its real bone-seeking clone sub-line for exploring the molecular mechanism of lung cancer metastasis.

METHODS

The cells came from the pleural effusion of a sixty-five years old female patient with lung adenocarcinoma and supraclavicular lymph node metastases. The gene expression was detected by real-time quantitative PCR. Intracardiac injection of the cells into nude mice was performed and in vivo imaging was obtained by bone scintigraphy and conventional radiography. Bone metastases were determined on bone scintigraphy and then the lesions were resected under deep anesthesia for bone metastasis cancer cell culture. The process was repeated for four cycles to obtain a real bone-seeking clone.

RESULTS

The tumorigenesis rate started at 4th passage in immunodeficient mice via subcutaneously and as well as later passages. Approximately 1×10⁶ cancer cells were injected into left cardiac ventricle of immunodeficient mice resulted bone metastasis sites were successfully revealed by bone scintigraphy and pathological diagnosis, the mandible (100%), scapula (33%), humerus (50%), vertebral column (50%), femur (66.7%) and accompanied invasion with other organs, the adrenal gland (17%), pulmonary (33%), liver (50%), submaxillary gland (33%) in the mice after inoculation two-three weeks. The chromosome karyotype analysis of the cells was subdiploid. Quantitative real-time PCR was used to examined and compared with SPC-A-1 lung adenocarcinoma, ESM1, VEGF-C, IL-6, IL-8, AR, SVIL, FN1 genes were overexpress. The novel cell was named CPA-Yang3. The femur metastasis cell was repeated in vivo-in vitro-in vivo with three cycles and harvested a real bone metastasis clone. It was named CPA-Yang3BM.

CONCLUSIONS

Tne characteristics of novel strain CPAYang3 is a highly metastasis cell line of Chinese lung adenocarcinoma and CPA-Yang3BM is a real bone-seeking clone.